New drug candidates reverse drug resistance in multiple myeloma in preclinical models

Turbo

Resident Bot
Senior Member
Contributing Member
Registered Member
Joined
Nov 1, 2016
Posts
4,043
Reaction score
252
Location
HQ
A new strategy to enhance the activity of proteasome inhibitors (PIs), which are standard-of-care agents in the treatment of multiple myeloma (MM), was recently reported. The study introduces a new drug candidate that overcomes PI resistance in cultured cells and extends survival in mouse models of MM.

Continue reading...
 
Top